DBV Technologies S.A. (NASDAQ:DBVT) Sees Significant Increase in Short Interest

DBV Technologies S.A. (NASDAQ:DBVT) saw a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 298,500 shares, a growth of 7.1% from the August 31st total of 278,800 shares. Based on an average daily volume of 48,300 shares, the days-to-cover ratio is presently 6.2 days. Currently, 0.3% of the shares of the company are short sold.

DBV Technologies Trading Up 1.4 %

NASDAQ:DBVT traded up $0.01 during mid-day trading on Tuesday, reaching $0.71. 36,012 shares of the stock were exchanged, compared to its average volume of 52,006. The business has a fifty day moving average price of $0.86 and a 200 day moving average price of $1.06. DBV Technologies has a 1-year low of $0.50 and a 1-year high of $2.74. The firm has a market capitalization of $68.51 million, a PE ratio of -0.83 and a beta of 0.68.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.08). The business had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. During the same period in the prior year, the firm earned ($0.26) EPS. On average, sell-side analysts forecast that DBV Technologies will post -1.43 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on DBVT shares. StockNews.com assumed coverage on DBV Technologies in a research report on Friday. They set a “hold” rating for the company. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of DBV Technologies in a research note on Thursday, August 1st. Finally, JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of DBV Technologies in a research note on Tuesday, September 24th.

Institutional Investors Weigh In On DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. boosted its position in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the period. DBV Technologies accounts for 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent reporting period. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.